decision on the BLA within 60 days per FDA regulations. It was public information that the FDA decision was expected by the end of December 2001. On the morning in question, 27 December 2001, Peter Bacanovic, Stewart’s broker, was informed that Samuel Waksal, the CEO of ImClone, was looking to sell all of the family’s ImClone shares held at Merrill Lynch. Without speculating as to the phone conversations that happened that day between all the
spotlight on her for crimes of insider trading. A tip from her former broker Peter E. Bacanovic, persuaded her into selling her IMClone stock after sharing information about a close friend of Stewart’s getting rid of his shares. Stewart’s companion, Sam Waksal, was also the chief executive of IMClone Systems Inc. IMClone Systems is a well-known company specializing in the research and development of therapies treatments of cancer. The stock selling was provoked due to a leak of information about The Food
Stewart and Peter Bacanovic were indicted on criminal charges arising from Martha Stewarts December 27, 2001 sale of 3,928 shares of stock in ImClone Systems, Inc. ("ImClone"). ImClone is a biotechnology company whose then-chief executive officer, Samuel Waksal, was a friend of Stewart's and a client of Stewart's stockbroker at Merrill Lynch, defendant Peter Bacanovic. On December 25, 2001, ImClone learned that the Food and Drug Administration had rejected the company's application for approval of Erbitux
In 1874, Thomas Eakins took a second course in anatomy at Jefferson Medical College. He attended surgical lectures and clinics presided over by Professor Samuel D. Gross. Eakins painted “The Gross Clinic,” to show the emotion involved in medical procedures. It appears as if the doctors performing the surgery have emotionally removed themselves from the situation at hand. By removing themselves from the emotional aspects of the surgery, the doctors can complete the task much easier than they would